Open AccessWhat Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
Author(s) -
Anna Hung,
Eleanor M. Perfetto
Publication year - 2016
Publication title -
journal of managed care and specialty pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.126
H-Index - 63
eISSN - 2376-1032
pISSN - 2376-0540
DOI - 10.18553/jmcp.2016.22.7.773
Subject(s) - prescription drug , incentive , medicare part d , medical prescription , term (time) , medicine , drug , medline , medicare advantage , business , actuarial science , family medicine , health care , nursing , pharmacology , economics , microeconomics , economic growth , physics , quantum mechanics , political science , law
Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom